

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	08/734,592
Filing Date	October 22, 1996
First Named Inventor	Andrew Goodearl et al.
Title	Glial Mitogenic Factors, Their Pre
Art Unit	1647
Examiner Name	Stephen Gucker
Attorney Docket Number	1094-1-022/CIP4/D-B/C-A

I hereby appoint:



Practitioners associated with the Customer Number:

23565

OR



Practitioner(s) named below:

AUG 09 2004

Name	Registration Number
	TECH CENTER 1600/2900

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:



The address associated with the above-mentioned Customer Number:

OR



The address associated with Customer Number:

23565

OR

Firm or
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:



Applicant/Inventor.



Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Name

Jane Wasman, Esq., Executive Vice President

Signature

Date

7-21-04

Telephone

(914) 347-4300 x161


NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.



*Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**REVOCATION OF POWER OF
ATTORNEY WITH
NEW POWER OF ATTORNEY
AND
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	08/734,592
Filing Date	October 22, 1996
First Named Inventor	Andrew Goodearl et al.
Art Unit	1647
Examiner Name	Stephen Gucker
Attorney Docket Number	1094-1-022CIP4/D-B/C-A

I hereby revoke all previous powers of attorney given in the above-identified application.

☒ A Power of Attorney is submitted herewith.

OR

☐ I hereby appoint the practitioners associated with the Customer Number:

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with
Customer Number:

23565

OR

☐ Firm or
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Name Jane Wasman, Esq., Executive Vice President

Signature *Jane Wasman*

Date 7-21-04


Telephone 914-347-4300 x 161

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Andrew Goodearl; Paul Stroobant; Luisa Minghetti; Michael Waterfield; Mark Marchionni; Maio S. Chen; Ian Hiles

Application No./Patent No.: 08/734,592 Filed/Issue Date: October 22, 1996

Entitled: GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE

ACORDA THERAPEUTICS, INC.

a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☒ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is 50 %
in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Andrew Goodearl, Paul Stroobant, Luisa Minghetti To: Ludwig Institute for Cancer Research

The document was recorded in the United States Patent and Trademark Office at
Reel 6556, Frame 0263, or for which a copy thereof is attached.

2. From: Mark Marchionni and Maio Su Chen To: Cambridge NeuroScience

The document was recorded in the United States Patent and Trademark Office at
Reel 6556, Frame 0262, or for which a copy thereof is attached.

3. From: Cambridge NeuroScience To: Genes Pharmaceuticals, Inc

The document was recorded in the United States Patent and Trademark Office at
Reel 011812, Frame 0784, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

7-21-04
Date

(914) 347-4300 x161

Telephone number

Jane Wasman, Esq., Executive Vice President

Typed or printed name

Jane Wasman

Signature

Exec. Vice President / General Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



00200R
UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

AUGUST 06, 2001

PTAS

CLARK & ELBING, LLP
KRISTINA BIEKER-BRADY, PH.D.
176 FEDERAL STREET
BOSTON, MA 02110



101730121A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 05/21/2001

REEL/FRAME: 011812/0784
NUMBER OF PAGES: 3

BRIEF: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

CAMBRIDGE NEUROSCIENCE, INC.

DOC DATE: 01/18/2001

ASSIGNEE:

CENES PHARMACEUTICALS, INC.
333 PROVIDENCE HIGHWAY
NORWOOD, MASSACHUSETTS 02062

SERIAL NUMBER: 08469549
PATENT NUMBER:

FILING DATE: 06/06/1995
ISSUE DATE:

SERIAL NUMBER: 08471833
PATENT NUMBER:

FILING DATE: 06/06/1995
ISSUE DATE:

SERIAL NUMBER: 08472065
PATENT NUMBER:

FILING DATE: 06/06/1995
ISSUE DATE:

SERIAL NUMBER: 08734665
PATENT NUMBER:

FILING DATE: 10/22/1996
ISSUE DATE:

SERIAL NUMBER: 08735010
PATENT NUMBER:

FILING DATE: 10/22/1996
ISSUE DATE:

SERIAL NUMBER: 08736070
PATENT NUMBER:

FILING DATE: 10/22/1996
ISSUE DATE:

SERIAL NUMBER: 08736019
PATENT NUMBER:

FILING DATE: 10/22/1996
ISSUE DATE:

SERIAL NUMBER: 08734592
PATENT NUMBER:

FILING DATE: 10/22/1996
ISSUE DATE:

SERIAL NUMBER: 09493799
PATENT NUMBER:

FILING DATE: 01/28/2000
ISSUE DATE:

SERIAL NUMBER: 08209204
PATENT NUMBER:

FILING DATE: 03/08/1994
ISSUE DATE:

SERIAL NUMBER: 08461097
PATENT NUMBER:

FILING DATE: 06/05/1995
ISSUE DATE:

SERIAL NUMBER: 08467602
PATENT NUMBER:

FILING DATE: 06/06/1995
ISSUE DATE:

SERIAL NUMBER: 08468731
PATENT NUMBER:

FILING DATE: 06/06/1995
ISSUE DATE:

SERIAL NUMBER: 09525492
PATENT NUMBER:

FILING DATE: 03/15/2000
ISSUE DATE:

SERIAL NUMBER: 09069784
PATENT NUMBER:

FILING DATE: 04/29/1998
ISSUE DATE:

SERIAL NUMBER: 09366886
PATENT NUMBER:

FILING DATE: 08/04/1999
ISSUE DATE:

SERIAL NUMBER: 09298121
PATENT NUMBER:

FILING DATE: 04/23/1999
ISSUE DATE:

SERIAL NUMBER: 09530884
PATENT NUMBER:

FILING DATE: 08/29/2000
ISSUE DATE:

SERIAL NUMBER: 08411295
PATENT NUMBER:

FILING DATE: 03/27/1995
ISSUE DATE:

SERIAL NUMBER: 08036555
PATENT NUMBER: 5530109

FILING DATE: 03/24/1993
ISSUE DATE: 06/25/1996

~~SERIAL NUMBER: 08249322~~
~~PATENT NUMBER: 5716930~~

~~FILING DATE: 05/26/1994~~
~~ISSUE DATE: 02/10/1998~~

SERIAL NUMBER: 08471855
PATENT NUMBER: 5621081

FILING DATE: 06/06/1995
ISSUE DATE: 04/15/1997

SERIAL NUMBER: 08469569	FILING DATE: 06/06/1995
PATENT NUMBER: 5606032	ISSUE DATE: 02/25/1997
SERIAL NUMBER: 08469526	FILING DATE: 06/06/1995
PATENT NUMBER: 5792849	ISSUE DATE: 08/11/1998
SERIAL NUMBER: 08470335	FILING DATE: 06/06/1995
PATENT NUMBER: 6147190	ISSUE DATE: 11/14/2000
SERIAL NUMBER: 08472008	FILING DATE: 06/06/1995
PATENT NUMBER: 5602096	ISSUE DATE: 02/11/1997
SERIAL NUMBER: 08734664	FILING DATE: 10/22/1996
PATENT NUMBER: 6204241	ISSUE DATE: 03/20/2001
SERIAL NUMBER: 08735021	FILING DATE: 10/22/1996
PATENT NUMBER: 6194377	ISSUE DATE: 02/27/2001
SERIAL NUMBER: 08734591	FILING DATE: 10/22/1996
PATENT NUMBER: 5854220	ISSUE DATE: 12/29/1998
SERIAL NUMBER: 07654104	FILING DATE: 02/11/1991
PATENT NUMBER: 5312928	ISSUE DATE: 05/17/1994
SERIAL NUMBER: 07854496	FILING DATE: 03/20/1992
PATENT NUMBER: 5298657	ISSUE DATE: 03/29/1994
SERIAL NUMBER: 08192990	FILING DATE: 02/08/1994
PATENT NUMBER: 5489709	ISSUE DATE: 02/06/1996
SERIAL NUMBER: 08469660	FILING DATE: 06/06/1995
PATENT NUMBER: 5876973	ISSUE DATE: 03/02/1999
SERIAL NUMBER: 08293465	FILING DATE: 08/19/1994
PATENT NUMBER: 5681568	ISSUE DATE: 10/28/1997
SERIAL NUMBER: 08341018	FILING DATE: 11/17/1994
PATENT NUMBER: 6087323	ISSUE DATE: 07/11/2000
SERIAL NUMBER: 08311365	FILING DATE: 09/23/1994
PATENT NUMBER: 5594114	ISSUE DATE: 01/14/1997
SERIAL NUMBER: 08470339	FILING DATE: 06/06/1995
PATENT NUMBER: 6232286	ISSUE DATE: 05/15/2001

JACQUELINE MOORE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

05-24-2001

AUG 02 2004



Substitute Form PTO-1595

101730121

Attorney Docket Numbers: 04585/

00200E, 00200F, 00200H, 00200I, 00200M, 00200N, 00200Q, 00200R, 00200S, 028001, 028002, 028003, 028004, 028006, 041004, 041005, 044001, 048002, 039001, 002005, 002006, 002007, 002009, 00200A, 00200B, 00200G, 00200J, 00200L, 00200P, 003001, 011001, 011002, 017009, 040001, 041001, 051001, 002008

Certificate of Mailing: Date of Deposit May 17, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to BOX ASSIGNMENT, Commissioner, United States Patent and Trademark Office, Washington, D.C. 20231.

Printed Name of Person Mailing Correspondence

Signature of Person Mailing Correspondence

RECORDATION FORM COVER SHEET PATENTS ONLY

Please record the attached document.

1. Previous name of assignee: Cambridge NeuroScience, Inc. Additional names attached: NO	2. Current name and address of assignee: CeNeS Pharmaceuticals, Inc. 333 Providence Highway Norwood, MA 02062 MAY 21 2001 Additional names/addresses attached: NO
3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Change of Name <input type="checkbox"/> Other: _____ Execution Date: January 18, 2001	40 E
4. Application numbers or patent numbers: A. Patent Application Numbers: — 08/469,549 — 08/471,833 08/472,065 08/734,865 08/735,010 08/736,070 08/736,019 08/734,592 09/493,799 08/209,204 08/461,097 08/467,602 08/468,731 09/525,492 09/069,784 09/366,886 09/298,121 09/530,884 08/411,295	B. Patent Numbers: 5,530,109 5,716,930 5,621,081 5,606,032 5,792,849 6,147,190 5,602,096 6,204,241 6,194,377 5,854,220 5,312,928 5,298,657 5,489,709 5,876,973 5,681,568 6,087,323 5,594,114 6,232,286 AUG 09 2004 TECH CENTER 1606/2330

05/23/2001 DBYRNE 00000238 08469549

01 FC:581

1480.00 01

5. Name and address of party to whom correspondence concerning document should be mailed:

Kristina Bieker-Brady, Ph.D., Reg. No. 39,109
Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Customer No.: 21559

6. Total number of applications/patents involved: 37

7. Total fee (37 C.F.R. § 3.41): \$1,480

☒ Fee enclosed

☐ Authorized to charge deposit account

8. Deposit account number: 03-2095. If the fee above is being charged to deposit account, a duplicate copy of this cover sheet is attached. Please apply any additional charges, or any credits, to Deposit Account No. 03-2095.

DO NOT USE THIS SPACE

9. Statement and signature: *To the best of my knowledge and belief, the foregoing information is true and correct and the attached is the original document.*

Kristina Bieker-Brady, Ph.D.
Name of person signing


Signature


Date



21559

PATENT TRADEMARK OFFICE

State of Delaware
Office of the Secretary of State

PAGE 1

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "CAMBRIDGE NEUROSCIENCE, INC.", CHANGING ITS NAME FROM "CAMBRIDGE NEUROSCIENCE, INC." TO "CENTES PHARMACEUTICALS, INC.", FILED IN THIS OFFICE ON THE EIGHTEENTH DAY OF JANUARY, A.D. 2001, AT 9 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor


Secretary of State

2078819 8100

010028302

AUTHENTICATION: 0922054

DATE: 01-18-01



PATENT

ATTORNEY DOCKET NOS. 04585/

00200E, 00200F, 00200H, 00200I, 00200M, 00200N, 00200Q, 00200R, 00200S, 028001, 028002, 028003, 028004, 028006, 041004, 041005, 044001, 048002, 039001, 002005, 002006, 002007, 002009, 00200A, 00200B, 00200G, 00200J, 00200L, 00200P, 003001, 011001, 011002, 017009, 046001, 041001, 051001, 002008

Certificate of Mailing: Date of Deposit: May 17, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Julie A. Bowen

Julie A. Bowen

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Conveying Party: Cambridge Neuroscience, Inc.

Receiving Party: CeNeS Pharmaceuticals, Inc.

Execution Date: January 18, 2001

Customer No.: 21559

Patent Nos.: 5,530,109; 5,716,930; 5,621,081;
5,606,032; 5,792,849; 6,147,190;
5,602,096; 6,204,241; 6,194,377;
5,854,220; 5,312,928; 5,298,657;
5,489,709; 5,876,973; 5,681,568;
6,087,323; 5,594,114; 6,232,286

Serial Nos.: 08/469,549; 08/471,833; 08/472,065;
08/734,665; 08/735,010; 08/736,070;
08/736,019; 08/734,592; 09/493,799;
08/209,204; 08/461,097; 08/467,602;
08/468,731; 09/525,492; 09/069,784;
09/366,886; 09/298,121; 09/530,884;
08/411,295

AUG 09 2004

TECH CENTER 1600/2900

Assignment Branch
Assistant Commissioner For Patents
Washington, D.C. 20231

SUBMISSION OF NAME CHANGE

Effective immediately, please change the name on all assignments as indicated on the attached Recordation Form Cover Sheet.

We are enclosing official document executed by the Secretary of State, State of Delaware, specifying the name change.

If there are any charges, or any credits, please apply them to Deposit Account No.

'03-2095.

Respectfully submitted,

Date:

May 17, 2001



Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559

PATENT TRADEMARK OFFICE

04585.001001 Submission of Name Change.wpd

ASSIGNMENT OF INVENTION

In consideration of the payment by ASIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

ASSIGNOR: CeNeS Pharmaceuticals plc
Compass House, Vision Park
Chivers Way, Histon
Cambridge CB4 9ZR
UK

(If assignment is by person or entity to whom invention was previously assigned and this was recorded in PTO add the following)

Recorded on: _____

Reel: _____

Frame: _____

Hereby sell, assign and transfer to

ASSIGNEE: Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne, New York 10532
U.S.A.

And the successors, assigns and legal representatives of the ASIGNEE the entire right, title and interest, including the right to sue for present, past and future infringement, in the United States, its territorial possessions, and in all foreign countries, including all treaty and convention rights in and to the invention and any and all improvements of the patents and patent applications listed on Schedule A attached hereto;

And any legal equivalent thereof in a foreign country, and, in and to, all United States and foreign Letters Patent, for the full term thereof, to be obtained for said invention by the above application or any continuation, division, renewal, extension or substitute thereof, and as to letters patents any re-issue or re-examination thereof.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue all such Letters Patent to ASSIGNEE:


ASSIGNOR further covenants to promptly provide all pertinent facts and documents known and accessible to ASSIGNOR relating to said invention and said Letters Patent and legal equivalents; to testify as to the same in any interference, litigation or proceeding related thereof; to execute and deliver any and all papers that may be necessary or desirable to perfect the title to said invention or any Letters Patents which may be granted therefore in said ASSIGNEE, its

successors, assigns or other legal representatives; to execute any additional or divisional applications for patents for said invention or any part or parts thereof, and for the reissue of any Letters Patents to be granted therefore; and to make all rightful oaths and do all lawful acts requisite for procuring the same or for aiding therein, all without further compensation, but at the sole expense of ASSIGNEE, its successors, assigns, or other legal representatives.

ASSIGNORS hereby grants ASSIGNEE and Assignee's attorneys the power to insert the Serial No. and/or filing date of the above-described application(s) after such information becomes known to them.

IN WITNESS WHEREOF, I have hereunto set hand and seal.

ASSIGNOR:



Dated: 28-02-07

SCHEDULE A

U.S. Patent No.	Issue Date	Title	Inventor(s)
✓ 5,530,109	06/25/1996	DNA ENCODING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
✓ 5,602,096	02/11/1997	METHOD OF USING A SECRETABLE GLIAL MITOGENIC FACTOR TO INDUCE ACETYLCHOLINE RECEPTOR SYNTHESIS	A. Goodearl et al.
✓ 6,147,190	11/14/2000	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 5,854,220	12/29/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 5,792,849	08/11/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 5,621,081	04/15/1997	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 5,606,032	02/28/1997	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 6,232,286	05/15/2001	METHOD OF PREPARING MITOGENS IN GLIAL CELLS USING GLIAL MITOGENIC FACTORS	A. Goodearl et al.
✓ 6,194,377	02/27/2001	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 5,716,930	02/10/1998	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 6,204,241	03/20/2001	METHOD FOR MAKING MITOGENS USING GLIAL CELLS	A. Goodearl et al.
✓ 6,444,642	09/03/2002	METHOD OF ENHANCING MYOTUBE FORMATION OR SURVIVAL OF MUSCLE CELL MITOGENS, DIFFERENTIATION OR STAYING WITH A NEUROGULIN	Robert Sklar et al.
✓ 5,594,114	01/14/1997	SECRETED CELL MITOGENIC FACTOR, ITS PREPARATION AND USE	A. Goodearl et al.
✓ 6,087,323	07/11/2000	USE OF NEUROGULIN AS MODULATORS OF CELLULAR COMMUNICATION	David Gwynne et al.
✓ 5,876,973	03/02/1999	METHOD FOR MAKING ANTIBODIES WHICH SPECIFICALLY BIND TO GLIAL GROWTH FACTORS	David Gwynne et al.

U.S. Patent Application No.	Filing Date	Title	Inventor(s)
✓ 08/471,833	06/06/1995	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/730,019	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/736,019	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/734,592	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/736,070	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/472,065	06/06/1995	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/735,010	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
✓ 08/469,549	06/06/1995	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.
08/734,665	10/22/1996	GLIAL MITOGENIC FACTORS, THEIR PREPARATION AND USE	A. Goodearl et al.

SCHEDULE A (Continued)

U.S. Patent Application No.	Filing Date	Title	Inventor(s)
08/461,097	06/05/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	R. Sklar et al.
08/468,731	06/06/1995	METHOD FOR TREATING MUSCLE DISEASES AND DISORDERS	R. Sklar et al.
08/411,295	03/27/1995	METHOD FOR TREATING DISORDERS OF THE EYE	T.A. Reh ET AL.
09/069,784	03/20/2001	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	D.I. GWYNNE ET AL.
09/366,886	08/04/1999	USE OF NEUREGULIN AS MODULATORS OF CELLULAR COMMUNICATION	D.I. GWYNNE ET AL.
09/298,121	04/23/1999	METHODS FOR TREATING CONGESTIVE HEART FAILURE	K. BINKER-BRADY ET AL.
09/530,884	10/18/1998	THERAPEUTICS METHODS COMPRISING USE OF A NEUREGULIN	R.M. MCBURNHY ET AL.